Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extended Chemotherapy with Neoadjuvant Carboplatin/Gemcitabine vs Adjuvant Paclitaxel/Gemcitabine in Ovarian Cancer
NCT00838656Phase 2Unknown
- Sponsor
- Warwick Medical School
- Start
- Oct 2007
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemcitabine in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (2 arms), sponsored by Warwick Medical School. Primary endpoint: Percentage of patients completing 12 courses of chemotherapy. Status: unknown.
02
Drugs
gemcitabine
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT00838656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00838656.